Literature DB >> 2127281

Pulsatile gonadotropin releasing hormone substitution following extirpation of suprasellar craniopharyngioma.

S Koloszár1, G Bártfai.   

Abstract

A craniopharyngioma growing suprasellarly attacks the medio-basal region of the hypothalamus, interrupting the production of gonadotropin-releasing hormone. In the case of a 15-year-old girl who underwent partial extirpation of craniopharyngioma, favorable endocrine effects were obtained by pulsatile gonadotropin-releasing hormone treatment. Gonadotropin-releasing hormone administered in a dose of 20 micrograms every 90 min resulted in the achievement of a menstrual cycle and ovulation. Together with surgical treatment, hormonal substitution plays an important role in the treatment of endocrine symptoms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127281     DOI: 10.1007/BF03349616

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

Review 1.  The neuroendocrine control of the menstrual cycle.

Authors:  E Knobil
Journal:  Recent Prog Horm Res       Date:  1980

2.  The use of gonadotropin-releasing hormone for the induction of ovulation.

Authors:  J H Liu; S S Yen
Journal:  Clin Obstet Gynecol       Date:  1984-12       Impact factor: 2.190

3.  Craniopharyngiomas: a critical approach to treatment.

Authors:  J M Cabezudo; J Vaquero; E Areitio; R Martinez; R G de Sola; G Bravo
Journal:  J Neurosurg       Date:  1981-09       Impact factor: 5.115

4.  Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas.

Authors:  A Martinez-Campos; J Cornejo; J Garza-Flores; F Velasco
Journal:  Fertil Steril       Date:  1985-10       Impact factor: 7.329

5.  Hypothalamic-pituitary function in patients with craniopharyngiomas.

Authors:  J S Jenkins; C J Gilbert; V Ang
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

6.  Galactorrhea, oligo/amenorrhea, and hyperprolactinemia in patients with craniopharyngiomas.

Authors:  L P Kapcala; M E Molitch; K D Post; B J Biller; R J Prager; I M Jackson; S Reichlin
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

7.  Stereotaxic intracavitary irradiation for cystic craniopharyngiomas.

Authors:  I F Pollack; L D Lunsford; T L Slamovits; L W Gumerman; G Levine; A G Robinson
Journal:  J Neurosurg       Date:  1988-02       Impact factor: 5.115

8.  Growth hormone treatment in children with craniopharyngioma: final growth status.

Authors:  E C Burns; J M Tanner; M A Preece; N Cameron
Journal:  Clin Endocrinol (Oxf)       Date:  1981-06       Impact factor: 3.478

9.  Internal irradiation for cystic craniopharyngioma.

Authors:  T Kobayashi; N Kageyama; K Ohara
Journal:  J Neurosurg       Date:  1981-12       Impact factor: 5.115

10.  Abnormal serum melatonin levels in patients with intrasellar tumors.

Authors:  R J Dempsey; W F Chandler
Journal:  Neurosurgery       Date:  1984-12       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.